100 related articles for article (PubMed ID: 27047749)
1. Further study of circulating IgG antibodies to CD25-derived peptide antigens in nonsmall cell lung cancer.
Chen C; Wang W; Meng Q; Wu N; Wei J
FEBS Open Bio; 2016 Mar; 6(3):211-5. PubMed ID: 27047749
[TBL] [Abstract][Full Text] [Related]
2. Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer.
Ye L; Wang W; Chen C; Meng Q; Yu Y
FEBS Open Bio; 2015; 5():809-12. PubMed ID: 26566475
[TBL] [Abstract][Full Text] [Related]
3. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
Wang J; Xu Y; Zhao H; Zhang X
J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
[TBL] [Abstract][Full Text] [Related]
5. Investigation of circulating antibodies to ANXA1 in breast cancer.
Huang Y; Zhang C; Chen C; Sun S; Zheng H; Wan S; Meng Q; Chen Y; Wei J
Tumour Biol; 2015 Feb; 36(2):1233-6. PubMed ID: 25344217
[TBL] [Abstract][Full Text] [Related]
6. Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
Wang W; Zhong W; Chen C; Meng Q; Wei J
Anticancer Res; 2017 Jun; 37(6):3151-3155. PubMed ID: 28551657
[TBL] [Abstract][Full Text] [Related]
7. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
[TBL] [Abstract][Full Text] [Related]
8. Plasma anti-BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer.
Zhao H; Zhang X; Han Z; Wang Z; Wang Y
FEBS Open Bio; 2018 May; 8(5):829-835. PubMed ID: 29744296
[TBL] [Abstract][Full Text] [Related]
9. Circulating anti-p16a IgG autoantibodies as a potential prognostic biomarker for non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Wang Y
FEBS Open Bio; 2018 Nov; 8(11):1875-1881. PubMed ID: 30410866
[TBL] [Abstract][Full Text] [Related]
10. Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer.
Xu Y; Jin Y; Liu L; Zhang X; Chen Y; Wei J
FEBS Open Bio; 2015; 5():198-201. PubMed ID: 25853035
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
[TBL] [Abstract][Full Text] [Related]
12. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
Liu S; Zhang X; Jiang Q; Liang T
FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
[TBL] [Abstract][Full Text] [Related]
13. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
[TBL] [Abstract][Full Text] [Related]
14. Circulating antibodies to p16 protein-derived peptides in breast cancer.
Chen C; Huang Y; Zhang C; Liu T; Zheng HE; Wan S; Sun S; Meng Q; Chen Y; Wei J
Mol Clin Oncol; 2015 May; 3(3):591-594. PubMed ID: 26137272
[TBL] [Abstract][Full Text] [Related]
15. Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
Du KL; Ji WT; Jiang QH; Wang Y
Clin Lab; 2023 May; 69(5):. PubMed ID: 37145070
[TBL] [Abstract][Full Text] [Related]
16. Further Study of Circulating Antibodies to P16, CD25 and FOXP3 in Hepatocellular Carcinoma.
Wang J; Xu Y; Wang Y; Zhang X; Zhang G
Onco Targets Ther; 2019; 12():10487-10493. PubMed ID: 31819529
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating IgG antibodies to apolipoprotein B100 in acute myocardial infarction.
Zhang X; Zhang X; Lei M; Lin Y; Megson IL; Wei J; Yu B; Jin Y
FEBS Open Bio; 2015; 5():712-6. PubMed ID: 26425439
[TBL] [Abstract][Full Text] [Related]
18. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of CD4+ CD25+ regulatory T-cells detection in tumor-draining lymph nodes of nonsmall cell lung cancer patients].
Su YJ; Ren K; Li H; Ren XB; Wang CL
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):922-6. PubMed ID: 18478932
[TBL] [Abstract][Full Text] [Related]
20. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
